Skip to content

Contineum Therapeutics, Inc.

CTNM

CIK 0001855175

← back to feed
Revenue (TTM)
$50M
−100.0% YoY Q1 Mar 2026
Net Income (TTM)
−$59.28M
−41.9% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$1.80
+0.5% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-135.7%
Q1 Mar 2026
Net Margin
-118.6%
Q1 Mar 2026
Free Cash Flow (TTM)
−$44.46M
Q1 Mar 2026
Cash
$20.16M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
23.1M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings